A history of RocheWe explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine ...

Roche’s move into digital pathology has been lifted by FDA approval of its digital pathology toolkit as an aid to clinical diagnosis.

Abstract Summary Pharmacological enhancement of endoplasmic reticulum (ER) proteostasis is an attractive strategy to mitigate pathology linked to etiologically-diverse protein misfolding diseases.

Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data.

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in ...

Roche and Eli Lilly have started testing a blood test that could be used to diagnose Alzheimer’s before symptoms arise, providing an alternative to expensive brain scans and speeding up the ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.

Roche’s tiragolumab worsens outcomes in lung cancer trial, raising further doubt about the TIGIT class of immune checkpoint inhibitors.

Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion. The Financial Times first revealed the ...

Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme ...

Bill Anderson's replacement as chief executive of Roche Pharmaceuticals has been announced, with head of global product strategy Teresa Graham stepping up into the role. Anderson's departure was ...